The unit – also known as Anew Therapeutics or ByteDance AI Drug Discovery – operates from Shanghai, Singapore and San Jose, California.
Its official website listed 36 core members, as well as big names on its “scientific advisory board”: Liu Yongjun, former president of Innovent Biologics, Ji Ma, a former principal scientist at biotech company Amgen, and Hua Zou, scientific director of protein chemistry at Takeda California.
Advertisement
In mid-April, Chris Li, head of biology, presented one of Anew Labs’ four pipeline drug candidates at Immunology2026 in Boston, organised by the American Association of Immunologists. The treatment was designed by generative AI for certain autoimmune diseases.
She Yuli, head of data, joined the International Conference on Learning Representations, in late April in Rio de Janeiro, according to She’s LinkedIn post. The conference was a gathering of professionals dedicated to the advancement of deep learning.

Yu Haoyu, head of computational chemistry, said on LinkedIn that he would be in Barcelona, Spain, for the 2026 Free Energy Workshop, which is for AI chemistry and kicks off on May 4. He planned to present AnewSampling, a framework to reproduce molecular dynamics at the all-atom level.

Don't Miss:
-
Lululemon apologises for China event with actor beating Japanese drum on Great Wall
-
Poverty line a limited marker, Hong Kong minister says, as aid focus expands to carers
-
Greece unveils Parthenon’s facade whole for first time in 220 years
-
US, Iran sign peace deal; China’s C919 jets grounded for safety checks: SCMP’s 7 highlights
-
Dragon Boat Festival drums up a buzz as unsettled weather fails to dampen spirits

India’s Zojila Tunnel Shores up Defense Posture in Himalayas
The Government Knows the Problem but Life not Getting Better
Cambodian Cyber Tycoon and ‘Singapore Washing’